QLINEA Stock Overview
Q-linea AB (publ) engages in the development of instruments and consumables for infection diagnostics in the United Kingdom.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Q-linea AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr2.07 |
| 52 Week High | kr10.30 |
| 52 Week Low | kr2.00 |
| Beta | 1.1 |
| 1 Month Change | -6.33% |
| 3 Month Change | -39.47% |
| 1 Year Change | -67.35% |
| 3 Year Change | -98.63% |
| 5 Year Change | -96.77% |
| Change since IPO | -96.93% |
Recent News & Updates
Recent updates
Here's Why Q-linea (STO:QLINEA) Must Use Its Cash Wisely
Dec 31
Will Q-linea (STO:QLINEA) Spend Its Cash Wisely?
May 07Q-linea (STO:QLINEA) Is In A Good Position To Deliver On Growth Plans
Jan 11We're Hopeful That Q-linea (STO:QLINEA) Will Use Its Cash Wisely
Feb 17
Do Institutions Own Q-linea AB (publ) (STO:QLINEA) Shares?
Dec 26Shareholder Returns
| QLINEA | SE Medical Equipment | SE Market | |
|---|---|---|---|
| 7D | -2.4% | -0.7% | -1.7% |
| 1Y | -67.4% | -8.8% | 8.1% |
Return vs Industry: QLINEA underperformed the Swedish Medical Equipment industry which returned -7.8% over the past year.
Return vs Market: QLINEA underperformed the Swedish Market which returned 8.8% over the past year.
Price Volatility
| QLINEA volatility | |
|---|---|
| QLINEA Average Weekly Movement | 6.9% |
| Medical Equipment Industry Average Movement | 7.1% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in SE Market | 13.0% |
| 10% least volatile stocks in SE Market | 3.4% |
Stable Share Price: QLINEA's share price has been volatile over the past 3 months.
Volatility Over Time: QLINEA's weekly volatility has decreased from 16% to 7% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 122 | Stuart Gander | qlinea.com |
Q-linea AB (publ) engages in the development of instruments and consumables for infection diagnostics in the United Kingdom. It offers ASTar, an antibiotic susceptibility testing system used for positive blood cultures; and in vitro diagnostics systems for infectious diseases. The company serves healthcare providers.
Q-linea AB (publ) Fundamentals Summary
| QLINEA fundamental statistics | |
|---|---|
| Market cap | kr241.85m |
| Earnings (TTM) | -kr229.37m |
| Revenue (TTM) | kr5.53m |
43.7x
P/S Ratio-1.1x
P/E RatioIs QLINEA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| QLINEA income statement (TTM) | |
|---|---|
| Revenue | kr5.53m |
| Cost of Revenue | kr3.45m |
| Gross Profit | kr2.09m |
| Other Expenses | kr231.45m |
| Earnings | -kr229.37m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 03, 2024
| Earnings per share (EPS) | -1.96 |
| Gross Margin | 37.74% |
| Net Profit Margin | -4,145.42% |
| Debt/Equity Ratio | 0% |
How did QLINEA perform over the long term?
See historical performance and comparison